PROFILPELAJAR.COM

Deleobuvir
Clinical data
Pregnancy; category	N/A;
Legal status
Legal status	Development terminated;
Identifiers
	IUPAC name (2E)-3-(2-{1-[2-(5-Bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carboxamido]cyclobutyl}-1-methyl-1H-benzimidazol- 6-yl)prop-2-enoic acid;
CAS Number	863884-77-9 ;
PubChem CID	56948249;
ChemSpider	29773345;
UNII	58BU988K90;
KEGG	D10554 ;
ChEMBL	ChEMBL2403318;
CompTox Dashboard (EPA)	DTXSID40235516 ;
Chemical and physical data
Formula	C34H33BrN6O3
Molar mass	653.581 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1C2=C(C=CC(=C2)C(=O)NC3(CCC3)C4=NC5=C(N4C)C=C(C=C5)/C=C/C(=O)O)C(=C1C6=NC=C(C=N6)Br)C7CCCC7;
	InChI InChI=1S/C34H33BrN6O3/c1-40-26-17-22(10-11-24(26)29(21-6-3-4-7-21)30(40)31-36-18-23(35)19-37-31)32(44)39-34(14-5-15-34)33-38-25-12-8-20(9-13-28(42)43)16-27(25)41(33)2/h8-13,16-19,21H,3-7,14-15H2,1-2H3,(H,39,44)(H,42,43)/b13-9+; Key:BMAIGAHXAJEULY-UKTHLTGXSA-N;

Deleobuvir (formerly BI 207127) was an experimental drug for the treatment of hepatitis C. It was being developed by Boehringer Ingelheim. It is a non-nucleoside hepatitis C virus NS5B polymerase inhibitor. Deleobuvir was tested in combination regimens with pegylated interferon and ribavirin, and in interferon-free regimens with other direct-acting antiviral agents including faldaprevir.^{[citation needed]}

Data from the SOUND-C2 study, presented at the 2012 AASLD Liver Meeting, showed that a triple combination of deleobuvir, faldaprevir, and ribavirin performed well in HCV genotype 1b patients.^[1] Efficacy fell below 50%, however, for dual regimens without ribavirin and for genotype 1a patients.^{[citation needed]}

These results were confirmed in the SOUND-C3 study, presented at the 2013 APASL Liver Conference, which found that 16-week triple therapy with deleobuvir + faldaprevir + ribavirin gave 95% SVR12 in HCV genotype 1b patients but poor virological response in genotype 1a.^[2]

In December 2013, Boehringer Ingelheim announced that the development of deleobuvir would not be continued since recent findings from phase III trials did not suggest sufficient efficacy.^{[citation needed]}